The definition of what constitutes a heart attack, also known as myocardial infarction (MI), and the data points used to create a best practices report for cardiac patient care has created a storm of controversy in the European cardiac field. The Clinical StudyThe...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for AbbVie’s RINVOQ™( Upadacitinib), a once-daily selective and reversible JAK inhibitor, for the treatment of adult patients with moderate to severe...

Kaiser Permanente Research radio recently interviewed Dr. Michael A Bookman, an oncologist and investigator with Kaiser, discussing his participation in an international clinical trial sponsored by AbbVie, focusing on a PARP inhibitor called Veliparib to treat ovarian...

Biopharma developing cancer therapies are in demand as the growing industry vies for bigger and more valuable pipelines. Seattle-based, privately held Mavupharma was the latest to feel the demand with its acquisition by AbbVie, which seeks to bolster its early-stage...

AbbVie and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of...

AbbVie announced the U.S. FDA has lifted the partial clinical hold placed on CANOVA, a Phase 3 trial evaluating venetoclax (Venclexta or Venclyxto) for the treatment of relapsed/refractory multiple myeloma. The CANOVA trial is evaluating venetoclax in combination with...

Popular Links

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.